Partner Headlines - GSK

  1. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  2. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  3. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  4. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  5. Benzinga's Volume Movers

    Benzinga
  6. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  7. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  8. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  9. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  10. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  11. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  12. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  13. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  14. Axovant IPO Best In 20 Years

    IBD
  15. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  16. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  17. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  18. Perrigo buys Glaxo OTC drugs

    IBD
  19. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  20. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  21. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  22. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  23. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  24. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  25. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  26. Glaxo more bullish than Q1

    IBD
  27. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  28. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  29. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  30. GlaxoSmithKline

    IBD
  31. Novartis EPS beats the Street

    IBD
  32. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  33. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  34. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  35. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  36. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  37. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  38. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  39. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  40. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  41. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  42. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  43. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  44. Benzinga's Weekend M&A Chatter

    Benzinga
  45. Gilead Sciences Still has More Upside

    GuruFocus
  46. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  47. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  48. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  49. Isis Pharma To Develop GI Drugs With J&J

    IBD
  50. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  51. Ebola Drug Work Continues

    IBD
  52. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
  53. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  54. Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR

    GuruFocus
  55. Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines

    Benzinga
  56. Pfizer Spreading Its Wings Into A New Domain Of Life Sciences

    GuruFocus
  57. Merck Bets $9.5 Billion On Cubist's War On Superbugs

    IBD
  58. GlaxoSmithKline's Move A Testament That Pharma Companies Are ...

    Benzinga
  59. The Top 5 European Stocks Held During Q3

    GuruFocus
  60. BioMarin buying Prosensa

    IBD
  61. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  62. Screening Pharma Stocks Amid Turnaround

    YCharts
  63. Jeff Auxier Buys Berkshire Hathaway in Third Quarter

    GuruFocus
  64. Apollo may make Glaxo offer

    IBD
  65. Irving Kahn Starts New Position In GlaxoSmithKline

    GuruFocus
  66. Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014

    GuruFocus
  67. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  68. Kahn Brothers' Third Quarter Numbers

    GuruFocus
  69. Ebola Vaccine Contenders

    Benzinga
  70. Stock Futures Upshift On Data; Yahoo, Broadcom, Boeing Climb

    IBD
  71. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  72. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  73. Sarepta Therapeutics Shares Up On Ebola Drug Safety Study

    Benzinga
  74. Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear

    IBD
  75. Ebola-Related Pharma Stocks Soar On First U.S. Case

    IBD
  76. Action Heats Up in Ebola-Related Equities

    FoxBusiness
  77. Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF

    GuruFocus
  78. Pharma Stocks: Surprising Shift In U.S. Drug Market

    YCharts
  79. Royal Bank of Scotland

    IBD
  80. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  81. International Securities For A Diversified Income Portfolio

    GuruFocus
  82. Could European Funds Offer An Opportunity Now?

    Benzinga
  83. Widely Held Guru Stocks Trading In Europe

    GuruFocus
  84. 3 Partnerships Pushing The Pharmaceutical Sector Forward

    Benzinga
  85. Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB

    GuruFocus
  86. China Fines Glaxo For Bribes

    IBD
  87. Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF

    GuruFocus
  88. Stock Futures Down, But Not Far; Alibaba Sets IPO Price Range

    IBD
  89. Benzinga's M&A Chatter for Wednesday August 27, 2014

    Benzinga
  90. GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) ...

    Benzinga
  91. InterMune Stock Spikes On Rare Big Biotech Buyout

    IBD
  92. 3 Dividend Kings From The U.K. I Love To Buy

    GuruFocus
  93. UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta ...

    Benzinga
  94. Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG

    GuruFocus
  95. Intermune up on buyout buzz

    IBD
  96. You Should Consider Adding GlaxoSmithKline Based on Tremendous ...

    GuruFocus
  97. Drugmaker AstraZeneca Returns To Growth

    IBD
  98. Widely Held Guru Stocks Near 52-Week Lows

    GuruFocus
  99. Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives ...

    Benzinga
  100. Glaxo, Sanofi Trend Up On Potential Deal For Established Brands

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!